カテゴリ： 世界, 医療/バイオ, QYResearch

希少疾病用医薬品の世界市場2023年：腫瘍内科、呼吸器内科、神経内科、血液内科、内分泌内科、循環器内科、代謝疾患、その他

■ 英語タイトル：Global Orphan Drugs Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA1657）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA1657
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：91
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[希少疾病用医薬品の世界市場2023年：腫瘍内科、呼吸器内科、神経内科、血液内科、内分泌内科、循環器内科、代謝疾患、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料は希少疾病用医薬品のグローバル市場について調査・分析し、世界の希少疾病用医薬品市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（腫瘍内科、呼吸器内科、神経内科、血液内科、内分泌内科、循環器内科、代謝疾患、その他）、用途別セグメント分析（乳幼児、中高生、大人、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Bristol-Myers Squibb、Roche、Novartis、Johnson & Johnson、Pfizer、Amgen、Sanofi、AstraZeneca、Takeda、Vertex Pharmaceuticals、AbbVie、Biogen、Eli Lillyなどが含まれています。希少疾病用医薬品のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、希少疾病用医薬品市場規模を算出する際に考慮しました。

・希少疾病用医薬品市場の概要
- 希少疾病用医薬品の種類別セグメント
- 世界の希少疾病用医薬品市場規模：タイプ別分析（腫瘍内科、呼吸器内科、神経内科、血液内科、内分泌内科、循環器内科、代謝疾患、その他）
- 希少疾病用医薬品の用途別セグメント
- 世界の希少疾病用医薬品市場規模：用途別分析（乳幼児、中高生、大人、その他）
- 世界の希少疾病用医薬品市場規模予測（2018年-2029年）

・希少疾病用医薬品市場の成長トレンド
- 希少疾病用医薬品の地域別市場規模（2018年-2029年）
- 希少疾病用医薬品市場ダイナミクス
- 希少疾病用医薬品の業界動向
- 希少疾病用医薬品市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：腫瘍内科、呼吸器内科、神経内科、血液内科、内分泌内科、循環器内科、代謝疾患、その他
- 世界の希少疾病用医薬品のタイプ別市場規模（2018年-2023年）
- 世界の希少疾病用医薬品のタイプ別市場規模（2024年-2029年）

・用途別セグメント：乳幼児、中高生、大人、その他
- 世界の希少疾病用医薬品の用途別市場規模（2018年-2023年）
- 世界の希少疾病用医薬品の用途別市場規模（2024年-2029年）

・希少疾病用医薬品の地域別市場規模
- 北米の希少疾病用医薬品市場規模（2018年-2029年）
- 米国の希少疾病用医薬品市場規模（2018年-2029年）
- ヨーロッパの希少疾病用医薬品市場規模（2018年-2029年）
- アジア太平洋の希少疾病用医薬品市場規模（2018年-2029年）
- 中国の希少疾病用医薬品市場規模（2018年-2029年）
- 日本の希少疾病用医薬品市場規模（2018年-2029年）
- 韓国の希少疾病用医薬品市場規模（2018年-2029年）
- インドの希少疾病用医薬品市場規模（2018年-2029年）
- オーストラリアの希少疾病用医薬品市場規模（2018年-2029年）
- 中南米の希少疾病用医薬品市場規模（2018年-2029年）
- 中東・アフリカの希少疾病用医薬品市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Bristol-Myers Squibb、Roche、Novartis、Johnson & Johnson、Pfizer、Amgen、Sanofi、AstraZeneca、Takeda、Vertex Pharmaceuticals、AbbVie、Biogen、Eli Lilly

・アナリストの観点/結論

・調査手法と情報源

An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases.
Highlights
The global Orphan Drugs market was valued at US$ 153130 million in 2022 and is anticipated to reach US$ 269210 million by 2029, witnessing a CAGR of 9.9% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Bristol-Myers Squibb is one of the most important global key players of orphan drugs, holds a share of about 10%, other key players include Roche and Novartis, etc. North America is the largest market, occupied for about 40 percent, followed by Asia-Pacific. In terms of type, oncology is the largest segment, with a share of over 60%, and in terms of application, the adult segment holds a share of about 40 percent.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Orphan Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Orphan Drugs.
The Orphan Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Orphan Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Orphan Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Bristol-Myers Squibb
Roche
Novartis
Johnson & Johnson
Pfizer
Amgen
Sanofi
AstraZeneca
Takeda
Vertex Pharmaceuticals
AbbVie
Biogen
Eli Lilly
Segment by Type
Oncology
Pulmonary
Neurology
Hematology
Endocrinology
Cardio-vascular
Metabolic Disorders
Others
Segment by Application
Baby and Child
Teenager
Adult
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Orphan Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Orphan Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oncology
1.2.3 Pulmonary
1.2.4 Neurology
1.2.5 Hematology
1.2.6 Endocrinology
1.2.7 Cardio-vascular
1.2.8 Metabolic Disorders
1.2.9 Others
1.3 Market by Application
1.3.1 Global Orphan Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Baby and Child
1.3.3 Teenager
1.3.4 Adult
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Orphan Drugs Market Perspective (2018-2029)
2.2 Orphan Drugs Growth Trends by Region
2.2.1 Global Orphan Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Orphan Drugs Historic Market Size by Region (2018-2023)
2.2.3 Orphan Drugs Forecasted Market Size by Region (2024-2029)
2.3 Orphan Drugs Market Dynamics
2.3.1 Orphan Drugs Industry Trends
2.3.2 Orphan Drugs Market Drivers
2.3.3 Orphan Drugs Market Challenges
2.3.4 Orphan Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Orphan Drugs Players by Revenue
3.1.1 Global Top Orphan Drugs Players by Revenue (2018-2023)
3.1.2 Global Orphan Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Orphan Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Orphan Drugs Revenue
3.4 Global Orphan Drugs Market Concentration Ratio
3.4.1 Global Orphan Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Orphan Drugs Revenue in 2022
3.5 Orphan Drugs Key Players Head office and Area Served
3.6 Key Players Orphan Drugs Product Solution and Service
3.7 Date of Enter into Orphan Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Orphan Drugs Breakdown Data by Type
4.1 Global Orphan Drugs Historic Market Size by Type (2018-2023)
4.2 Global Orphan Drugs Forecasted Market Size by Type (2024-2029)
5 Orphan Drugs Breakdown Data by Application
5.1 Global Orphan Drugs Historic Market Size by Application (2018-2023)
5.2 Global Orphan Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Orphan Drugs Market Size (2018-2029)
6.2 North America Orphan Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Orphan Drugs Market Size by Country (2018-2023)
6.4 North America Orphan Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Orphan Drugs Market Size (2018-2029)
7.2 Europe Orphan Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Orphan Drugs Market Size by Country (2018-2023)
7.4 Europe Orphan Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Orphan Drugs Market Size (2018-2029)
8.2 Asia-Pacific Orphan Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Orphan Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Orphan Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Orphan Drugs Market Size (2018-2029)
9.2 Latin America Orphan Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Orphan Drugs Market Size by Country (2018-2023)
9.4 Latin America Orphan Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Orphan Drugs Market Size (2018-2029)
10.2 Middle East & Africa Orphan Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Orphan Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Orphan Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Orphan Drugs Introduction
11.1.4 Bristol-Myers Squibb Revenue in Orphan Drugs Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Orphan Drugs Introduction
11.2.4 Roche Revenue in Orphan Drugs Business (2018-2023)
11.2.5 Roche Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Orphan Drugs Introduction
11.3.4 Novartis Revenue in Orphan Drugs Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Orphan Drugs Introduction
11.4.4 Johnson & Johnson Revenue in Orphan Drugs Business (2018-2023)
11.4.5 Johnson & Johnson Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Orphan Drugs Introduction
11.5.4 Pfizer Revenue in Orphan Drugs Business (2018-2023)
11.5.5 Pfizer Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Orphan Drugs Introduction
11.6.4 Amgen Revenue in Orphan Drugs Business (2018-2023)
11.6.5 Amgen Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Orphan Drugs Introduction
11.7.4 Sanofi Revenue in Orphan Drugs Business (2018-2023)
11.7.5 Sanofi Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Orphan Drugs Introduction
11.8.4 AstraZeneca Revenue in Orphan Drugs Business (2018-2023)
11.8.5 AstraZeneca Recent Development
11.9 Takeda
11.9.1 Takeda Company Detail
11.9.2 Takeda Business Overview
11.9.3 Takeda Orphan Drugs Introduction
11.9.4 Takeda Revenue in Orphan Drugs Business (2018-2023)
11.9.5 Takeda Recent Development
11.10 Vertex Pharmaceuticals
11.10.1 Vertex Pharmaceuticals Company Detail
11.10.2 Vertex Pharmaceuticals Business Overview
11.10.3 Vertex Pharmaceuticals Orphan Drugs Introduction
11.10.4 Vertex Pharmaceuticals Revenue in Orphan Drugs Business (2018-2023)
11.10.5 Vertex Pharmaceuticals Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Orphan Drugs Introduction
11.11.4 AbbVie Revenue in Orphan Drugs Business (2018-2023)
11.11.5 AbbVie Recent Development
11.12 Biogen
11.12.1 Biogen Company Detail
11.12.2 Biogen Business Overview
11.12.3 Biogen Orphan Drugs Introduction
11.12.4 Biogen Revenue in Orphan Drugs Business (2018-2023)
11.12.5 Biogen Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Detail
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Orphan Drugs Introduction
11.13.4 Eli Lilly Revenue in Orphan Drugs Business (2018-2023)
11.13.5 Eli Lilly Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Orphan Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Oncology
Table 3. Key Players of Pulmonary
Table 4. Key Players of Neurology
Table 5. Key Players of Hematology
Table 6. Key Players of Endocrinology
Table 7. Key Players of Cardio-vascular
Table 8. Key Players of Metabolic Disorders
Table 9. Key Players of Others
Table 10. Global Orphan Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 11. Global Orphan Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 12. Global Orphan Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 13. Global Orphan Drugs Market Share by Region (2018-2023)
Table 14. Global Orphan Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 15. Global Orphan Drugs Market Share by Region (2024-2029)
Table 16. Orphan Drugs Market Trends
Table 17. Orphan Drugs Market Drivers
Table 18. Orphan Drugs Market Challenges
Table 19. Orphan Drugs Market Restraints
Table 20. Global Orphan Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 21. Global Orphan Drugs Market Share by Players (2018-2023)
Table 22. Global Top Orphan Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs as of 2022)
Table 23. Ranking of Global Top Orphan Drugs Companies by Revenue (US$ Million) in 2022
Table 24. Global 5 Largest Players Market Share by Orphan Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Orphan Drugs Product Solution and Service
Table 27. Date of Enter into Orphan Drugs Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Orphan Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 30. Global Orphan Drugs Revenue Market Share by Type (2018-2023)
Table 31. Global Orphan Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 32. Global Orphan Drugs Revenue Market Share by Type (2024-2029)
Table 33. Global Orphan Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 34. Global Orphan Drugs Revenue Market Share by Application (2018-2023)
Table 35. Global Orphan Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 36. Global Orphan Drugs Revenue Market Share by Application (2024-2029)
Table 37. North America Orphan Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. North America Orphan Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 39. North America Orphan Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 40. Europe Orphan Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Europe Orphan Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 42. Europe Orphan Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 43. Asia-Pacific Orphan Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 44. Asia-Pacific Orphan Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 45. Asia-Pacific Orphan Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 46. Latin America Orphan Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Latin America Orphan Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 48. Latin America Orphan Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 49. Middle East & Africa Orphan Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 50. Middle East & Africa Orphan Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 51. Middle East & Africa Orphan Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 52. Bristol-Myers Squibb Company Detail
Table 53. Bristol-Myers Squibb Business Overview
Table 54. Bristol-Myers Squibb Orphan Drugs Product
Table 55. Bristol-Myers Squibb Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 56. Bristol-Myers Squibb Recent Development
Table 57. Roche Company Detail
Table 58. Roche Business Overview
Table 59. Roche Orphan Drugs Product
Table 60. Roche Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 61. Roche Recent Development
Table 62. Novartis Company Detail
Table 63. Novartis Business Overview
Table 64. Novartis Orphan Drugs Product
Table 65. Novartis Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 66. Novartis Recent Development
Table 67. Johnson & Johnson Company Detail
Table 68. Johnson & Johnson Business Overview
Table 69. Johnson & Johnson Orphan Drugs Product
Table 70. Johnson & Johnson Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 71. Johnson & Johnson Recent Development
Table 72. Pfizer Company Detail
Table 73. Pfizer Business Overview
Table 74. Pfizer Orphan Drugs Product
Table 75. Pfizer Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 76. Pfizer Recent Development
Table 77. Amgen Company Detail
Table 78. Amgen Business Overview
Table 79. Amgen Orphan Drugs Product
Table 80. Amgen Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 81. Amgen Recent Development
Table 82. Sanofi Company Detail
Table 83. Sanofi Business Overview
Table 84. Sanofi Orphan Drugs Product
Table 85. Sanofi Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 86. Sanofi Recent Development
Table 87. AstraZeneca Company Detail
Table 88. AstraZeneca Business Overview
Table 89. AstraZeneca Orphan Drugs Product
Table 90. AstraZeneca Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 91. AstraZeneca Recent Development
Table 92. Takeda Company Detail
Table 93. Takeda Business Overview
Table 94. Takeda Orphan Drugs Product
Table 95. Takeda Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 96. Takeda Recent Development
Table 97. Vertex Pharmaceuticals Company Detail
Table 98. Vertex Pharmaceuticals Business Overview
Table 99. Vertex Pharmaceuticals Orphan Drugs Product
Table 100. Vertex Pharmaceuticals Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 101. Vertex Pharmaceuticals Recent Development
Table 102. AbbVie Company Detail
Table 103. AbbVie Business Overview
Table 104. AbbVie Orphan Drugs Product
Table 105. AbbVie Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 106. AbbVie Recent Development
Table 107. Biogen Company Detail
Table 108. Biogen Business Overview
Table 109. Biogen Orphan Drugs Product
Table 110. Biogen Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 111. Biogen Recent Development
Table 112. Eli Lilly Company Detail
Table 113. Eli Lilly Business Overview
Table 114. Eli Lilly Orphan Drugs Product
Table 115. Eli Lilly Revenue in Orphan Drugs Business (2018-2023) & (US$ Million)
Table 116. Eli Lilly Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Orphan Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Orphan Drugs Market Share by Type: 2022 VS 2029
Figure 3. Oncology Features
Figure 4. Pulmonary Features
Figure 5. Neurology Features
Figure 6. Hematology Features
Figure 7. Endocrinology Features
Figure 8. Cardio-vascular Features
Figure 9. Metabolic Disorders Features
Figure 10. Others Features
Figure 11. Global Orphan Drugs Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 12. Global Orphan Drugs Market Share by Application: 2022 VS 2029
Figure 13. Baby and Child Case Studies
Figure 14. Teenager Case Studies
Figure 15. Adult Case Studies
Figure 16. Other Case Studies
Figure 17. Orphan Drugs Report Years Considered
Figure 18. Global Orphan Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 19. Global Orphan Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 20. Global Orphan Drugs Market Share by Region: 2022 VS 2029
Figure 21. Global Orphan Drugs Market Share by Players in 2022
Figure 22. Global Top Orphan Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs as of 2022)
Figure 23. The Top 10 and 5 Players Market Share by Orphan Drugs Revenue in 2022
Figure 24. North America Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. North America Orphan Drugs Market Share by Country (2018-2029)
Figure 26. United States Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Canada Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Europe Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Europe Orphan Drugs Market Share by Country (2018-2029)
Figure 30. Germany Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Asia-Pacific Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Asia-Pacific Orphan Drugs Market Share by Region (2018-2029)
Figure 38. China Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Japan Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. South Korea Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Southeast Asia Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. India Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Australia Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Latin America Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Latin America Orphan Drugs Market Share by Country (2018-2029)
Figure 46. Mexico Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Brazil Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Orphan Drugs Market Share by Country (2018-2029)
Figure 50. Turkey Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Saudi Arabia Orphan Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 53. Roche Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 54. Novartis Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 55. Johnson & Johnson Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 56. Pfizer Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 57. Amgen Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 58. Sanofi Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 59. AstraZeneca Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 60. Takeda Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 61. Vertex Pharmaceuticals Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 62. AbbVie Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 63. Biogen Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 64. Eli Lilly Revenue Growth Rate in Orphan Drugs Business (2018-2023)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 眼科用機器/医薬品の世界市場2023年：眼科機器、眼科用医薬品
  • 薬剤耐性結核治療薬の世界市場2023年：第一類抗結核薬、第二類抗結核薬、その他
  • コウニス症候群治療の世界市場2023年：β-ラクタム系抗生物質、非ステロイド性抗炎症薬、ロクロニウム、その他
  • 抗凝固薬の世界市場2023年：注射用抗凝固薬、経口抗凝固薬
  • 一般用医薬品の世界市場2023年：消化器、皮膚科、耳鼻咽喉科、栄養/ビタミン、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA1657 )"希少疾病用医薬品の世界市場2023年：腫瘍内科、呼吸器内科、神経内科、血液内科、内分泌内科、循環器内科、代謝疾患、その他" (英文：Global Orphan Drugs Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。